CNR-400
Neurodegenerative Disorders (e.g., Alzheimer’s, FTD)
PreclinicalActive
Key Facts
Indication
Neurodegenerative Disorders (e.g., Alzheimer’s, FTD)
Phase
Preclinical
Status
Active
Company
About Canurta
AI‑enabled botanical drug developer targeting ALS and inflammatory diseases.
View full company profile